Historically, metformin and the sulfonylureas were the most-prescribed drugs for type 2 diabetes. These agents dominated the early lines of therapy until disease progression required insulin replacement. However, the emergence of more-effective, safer, and/or better-tolerated therapies, such as the dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium glucose contransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists, has provided physicians with a much broader array of therapeutic options. Moreover, because of a better understanding of type 2 diabetes and its complications, treatment is becoming more individualized. Numerous branded agents from both established and new drug classes are now jostling for position in the treatment paradigm.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
KEY DRUGS COVERED
Afrezza, Apidra, Basaglar, Bydureon, Byetta, Farxiga, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza
KEY ANALYSIS PROVIDED